NASDAQ: FTREFortrea Holdings Inc Stock
$37.41+0.76 (+2.07%)
Updated May 3, 2024
FTRE Price
$37.41
Fair Value Price
$52.03
Market Cap
$3.34B
52 Week Low
$24.93
52 Week High
$41.02
P/E
-935.25x
P/B
1.92x
P/S
1x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.11B
Earnings
-$3.40M
Gross Margin
16.7%
Operating Margin
2.28%
Profit Margin
-0.1%
Debt to Equity
1.51
Operating Cash Flow
$167M
Beta
1.18
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
FTRE Overview
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FTRE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FTRE ($37.41) is undervalued by 28.1% relative to our estimate of its Fair Value price of $52.03 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
FTRE ($37.41) is significantly undervalued by 28.1% relative to our estimate of its Fair Value price of $52.03 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
FTRE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FTRE due diligence checks available for Premium users.
Be the first to know about important FTRE news, forecast changes, insider trades & much more!
FTRE News
Valuation
FTRE fair value
Fair Value of FTRE stock based on Discounted Cash Flow (DCF)
Price
$37.41
Fair Value
$52.03
Undervalued by
28.10%
FTRE ($37.41) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FTRE ($37.41) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FTRE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FTRE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-935.25x
Industry
6.05x
Market
35.94x
FTRE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.92x
Industry
6.01x
FTRE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FTRE's financial health
Profit margin
Revenue
$775.4M
Net Income
-$36.0M
Profit Margin
-4.6%
FTRE's Earnings (EBIT) of $70.90M... subscribe to Premium to read more.
Interest Coverage Financials
FTRE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$4.4B
Liabilities
$2.6B
Debt to equity
1.51
FTRE's short-term assets ($1.25B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FTRE's long-term liabilities ($1.84B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FTRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$12.4M
Investing
-$9.0M
Financing
-$4.6M
FTRE's operating cash flow ($167.40M)... subscribe to Premium to read more.
Debt Coverage Financials
FTRE vs Biotech Stocks
Fortrea Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.